702. CAR-T Cell Therapies: Basic and Translational: Poster II

TCF 1 overexpression enhances CD19 CAR T cell potency by attenuating activation induced cell death

Intein based modular assembly of multi receptor CAR T cells

Dual armoring of CLL 1 CAR T cells with IL 18 and an RQR8 suicide switch enhances efficacy and safety in Acute Myeloid Leukemia

Development of next generation multi antigen targeting off the shelf CAR T cells for conditioning free treatment of B cell lymphoma

Precision targeting of pathogenic B cells and autoantibodies in systemic lupus erythematosus using CAR T cells against the IGHV4 34 B cell receptor

B lineage acute lymphoblastic leukaemia disrupts a LepR bone marrow stromal niche which is critical for CAR T cell persistence

Allogeneic CD19 directed CAR T cell therapy derived from umbilical cord blood for relapsed acute lymphoblastic leukemia

Mitochondrial mass in pre lymphodepletion T cells predicts early response to CAR T therapy in relapsed refractory non Hodgkin lymphoma

Impact of antibiotic timing on survival outcomes in CD19 and BCMA CAR T cell therapy

Development of a novel CAR T cell therapy using a multimodal approach to target T cell lymphoma

This is a title in sentence case synnotch CD123 and CLL1 CAR T can specifically target AML to avoid the off target effects

Genome wide CRISPR screening identifies CRL1 as a therapeutic target for restoring CD19 expression and improving immunotherapy efficacy in  B cell malignancies

PI3 kinase inhibition reduces CAR T cell trogocytosis mediated fratricide

Temporal control of CAR expression enables thymic generation of autoreactive T cells targeting tumor associated antigens

Live imaging of human xenogeneic CART cells in a clinical trial of companion dogs with lymphoma

Synkir 310 split signaling based KIR CAR T cell therapy achieves faster and deeper anti B cell tumor efficacy with reduced cytokine levels

High affinity PD 1 CD28 switch receptor enhances sustained antitumor activity of CAR T cells in both lymphoma and ewing sarcoma

Single cell dissection of CAR T and blinatumomab elicited T cell states uncovers therapy specific functional decay patterns

Comparative high dimensional profiling reveals distinct immune reconstitution dynamics between CD19 and CD7 CAR T therapies in acute leukemia

CD83 CAR T overcome CD19 antigen loss in B cell malignancies after CD19 directed therapy

SMARCA4 deletion enhances CAR T cell cytotoxicity and persistence against cancer